About: Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$20.68 (+0.68%)
NEU ASX Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Ltd share price
NEU price activity
Last Price
$20.680
Change (24hr)
0.14 AUD (0.68%)
Volume
586.91K
Volume (4w avg)
-
Open
$20.98
Day Range
$20.44 - $21.09
Previous Close
$20.54
Last Trade
18 Sep, 6:22 am GMT+0
Delayed
18 Sep, 6:22 am GMT+0
NEU price performance
Delayed
18 Sep, 6:22 am GMT+0
NEU Market Signals